Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
2.02
-0.04 (-2.18%)
Bozor ochiq: Aug 12, 2026, 11:50 AM EDT
2.06
0.00 (0.00%)
Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT
Century Therapeutics, Inc., biotexnologiya kompaniyasi, qattiq o'smalar, gematologik xavfli o'smalar va otoimmün kasalliklarni davolash uchun allogen hujayra terapiyalarini ishlab chiqish bilan shug'ullanadi. Uning asosiy mahsulot nomzodi CNTY-813 bo'lib, u iPSC dan olingan beta orolcha hujayralarini almashtirish terapiyasi bo'lib, 1-toifa diabetni davolash uchun Allo-Evasion 5.0 bilan ishlab chiqilgan. Kompaniya, shuningdek, B-hujayralari vositasida yuzaga keladigan otoimmün kasalliklarni davolash uchun Allo-Evasion 5.0 bilan ishlab chiqilgan CD19-ga yo'naltirilgan CD4+/CD8+ CAR-iT hujayra terapiyasi bo'lgan CNTY-308; va B-hujayralari vositasida yuzaga keladigan otoimmün kasalliklarni davolash uchun CD19 CAR ni ifoda qilish uchun ishlab chiqilgan oltita aniq gen tahriri bilan iPSC dan olingan allogen CAR-iNK hujayra terapiyasi bo'lgan CNTY-101ni ishlab chiqish bilan shug'ullanadi. Allo-Evasion 1.0 tahrirlari bilan. Century Therapeutics, Inc. 2018 yilda ro'yxatga olingan va shtab-kvartirasi Filadelfiyada, Pensilvaniya shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Brent Pfeiffenberger M.B.A., Pharm.D. | President, CEO & Chairman |
| Dr. Chad A. Cowan Ph.D. | Chief Scientific Officer |
| Dr. Gregory Russotti Ph.D. | Chief Technology & Manufacturing Officer |
| Krista Kauppinen J.D., Ph.D. | VP, General Counsel & Head of Intellectual Property |
| Michael Naso Ph.D. | Senior VP of Cell Engineering |
| Mr. Douglas Carr CPA | Senior VP of Finance & Operations, Principal Financial Officer and Secretary |
| Ms. Elizabeth Devlin | VP & Head of Development |
| Ms. Megan Bilson | Chief People Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-12 | 10-Q | ipsc-20260630x10q.htm |
| 2026-06-16 | 8-K | tm2617925d1_8k.htm |
| 2026-06-12 | 8-K | tm2617728d1_8k.htm |
| 2026-06-08 | 8-K | tm2617028d1_8k.htm |
| 2026-05-13 | 8-K | tm2614312d1_8k.htm |
| 2026-05-13 | 10-Q | ipsc-20260331x10q.htm |
| 2026-04-27 | DEF 14A | tm261507-6_def14a.htm |
| 2026-04-16 | PRE 14A | tm261507-4_pre14a.htm |
| 2026-04-16 | ARS | tm265719d2_ars.pdf |
| 2026-03-26 | 8-K | tm269823d1_8k.htm |